MedTrace Logo

Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

NCT03491371 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-04-10

No results posted yet for this study

Summary

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.

Conditions

  • Efficacy
  • Toxicity

Interventions

DRUG

Methylsulfonic apatinib

Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.

Sponsors & Collaborators

  • Peking University Shougang Hospital

    collaborator OTHER

  • Peking University International Hospital

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2016-12-31
Completion
2017-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03491371 on ClinicalTrials.gov